NFKB1 and neoplasm: NHE-06 administration decreased IL-6 levels and downregulated IL-1β and COX-2 expression in mice bearing subcutaneous Hepa1-6 tumors, which is indicative of inactivated NF-κB/IL-6/STAT3 signaling and restored tumor immunity without direct tumor cytotoxicity.